TrialNature communications2026

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.

Tim Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.